Overview

ARISE - Aggressive Reduction of Inflammation Stops Events

Status:
Unknown status
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
To assess the safety and efficacy of AGI-1067, as compared to placebo, in the treatment of vascular inflammation and atherosclerosis by assessing the reduction in cardiovascular events.
Phase:
Phase 3
Details
Lead Sponsor:
AtheroGenics